Guillain-Barré syndrome (GBS) is an acute inflammatory autoimmune disease affecting the peripheral nervous system. The characteristic features are progressive bilateral symmetric weakness and numbness in the legs and arms along with diminished or complete loss of deep tendon reflexes. In this presumed post-infectious, immune-mediated disease, cellular and humoral immune mechanisms probably play a vital developmental role. The production of autoantibodies or recruitment of inflammatory cells on the myelin sheath were thought to be responsible for the pathogenesis of GBS[@b1]. However, our present knowledge of the mechanism and epigenetic features of GBS remains insufficient.

Long noncoding RNAs (lncRNAs) are most commonly defined as transcripts longer than 200 nucleotides with little or no protein-coding capacity[@b2][@b3]. Since they cannot be completely dismissed as mere transcriptional "noise," lncRNAs have attracted increasing attention based on the development of lncRNA microarrays, high-throughput sequencing, and bioinformatics[@b4]. Although without protein coding capability, accumulating evidence has suggested that lncRNAs participate in a wide variety of biological processes, including genomic imprinting, cell differentiation, chromosome modification, X-chromosome silencing, organogenesis, chromosome dosage-compensation, transcriptional activation, *etc*.[@b5][@b6][@b7][@b8].

Currently, the role of lncRNA in autoimmune diseases has attracted considerable attention. Recent studies have reported that the activation, differentiation, and imbalanced expression of immune cells, including T cells, B cells, macrophages, and NK cells, may correlate directly with lncRNAs. Moreover, some specific lncRNAs also play a crucial role in autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), psoriasis, and autoimmune thyroid disease (AITD)[@b9].

Further, the molecular mechanisms underlying the contributions of lncRNAs to GBS are not clear. Therefore, in the present study, we applied microarray technology to examine lncRNA and message RNA (mRNA) expression profiles in blood samples from GBS patients and healthy controls. Additionally, results from gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses predicted that these abnormally expressed mRNAs and lncRNAs function in the development of GBS.

Results
=======

lncRNA and mRNA expression profile in GBS patients
--------------------------------------------------

To investigate the expression levels of lncRNAs and mRNAs associated with GBS, lncRNA and mRNA microarray analyses were performed on the peripheral blood mononuclear cells (PBMCs) of 15 GBS patients and 15 healthy controls. [Figure 1](#f1){ref-type="fig"} was the hierarchical clustering that showed the differentially expressed lncRNAs ([Fig. 1a](#f1){ref-type="fig"}) and mRNAs ([Fig. 1b](#f1){ref-type="fig"}) between GBS patients and healthy controls. The red and the green shades indicate the expression above and below the relative expression, respectively, across all samples.

Real-time quantitative PCR validation
-------------------------------------

To validate our results independently and determine the role of lncRNAs in GBS, we randomly selected 6 lncRNAs. As shown in [Fig. 2](#f2){ref-type="fig"}, differences in the expression of 6 lncRNAs were detected in GBS patients compared with healthy controls. LncRNA ENSG00000258601.1 was the most elevated (8.1-fold higher expression), followed by lncRNA ENSG00000227258.1 (3.94-fold higher expression), and lncRNA XLOC_004244 (3.64-fold higher expression). LncRNA ENSG00000257156.1, lncRNA ENSG00000237945.2, and lncRNA ENSG00000271964.1 exhibited 4.58-, 3.72- and 2.96- fold lower expression, respectively. These results were consistent with the results obtained from the microarray chip analyses.

Minimum Redundancy Maximal Relevance (mRMR) Result
--------------------------------------------------

After running the mRMR software, two outcomes were obtained. One was a MaxRel feature table ranking the 1246 mRNAs and 514 lncRNAs according to their relevance to the class of GBS patients or healthy controls (see File S1). The other, presented as the mRMR feature table, lists the top 310 mRNAs and 114 lncRNAs with the maximum relevance and minimum redundancy to the class of GBS patients or healthy controls (mRMR score equal 0 or 1, [Table 1](#t1){ref-type="table"} and [2](#t2){ref-type="table"}).

GO and KEGG pathway analyses of differentially expressed mRNAs
--------------------------------------------------------------

GO analysis was performed to investigate the over-representation of biological processes, cellular components, and specific molecular function associating protein-coding mRNAs, since no comprehensive annotation database is available for categorizing lncRNAs. A total of 310 filtered mRNAs (based on mRMR results) were included in GO analyses (see File S2). [Figure 3](#f3){ref-type="fig"} and [Table 3](#t3){ref-type="table"} show the top 29 GO from the differentially expressed mRNAs (−lg^P^ \> 2.5); these include cytosol, cellular macromolecular complex assembly, cell cycle, ligase activity, and protein catabolic process.

Furthermore, from the data in mRMR, top seven KEGG pathways were listed, as [Fig. 4](#f4){ref-type="fig"} depicts, including "Proteasome", "Spliceosome", "Citrate cycle (TCA cycle)", "NOD-like receptor signaling pathway", "Primary immunodeficiency", "Endocytosis" and "T cell receptor signaling pathway." Among them, "Proteasome" was the most significant, because it also appeared in the previous study[@b10].

lncRNA-mRNA co-expression network
---------------------------------

Co-expression network analysis was performed between the 114 differentially expressed lncRNAs and the 310 differentially expressed mRNAs based on the mRMR results. In total, 113 lncRNAs and 303 mRNAs were included in the co-expression network. Moreover, our data showed that the co-expression network was composed of 5391 network nodes and 420 connections. The co-expression network indicated that one mRNA may correlate with 1--53 lncRNAs, and one lncRNA may correlate with 1 to 140 mRNAs (see File S3). Moreover, [Fig. 5](#f5){ref-type="fig"} reveals that 92 lncRNAs interacting with 6 mRNAs participated in the meaningful "Proteasome" pathway.

Discussion
==========

LncRNAs had long been considered as simply transcriptional noise[@b11]. However, recent studies showed that lncRNAs can regulate basal transcription, posttranscriptional processes, epigenetic modifications, DNA methylation, histone modification and even directly bind proteins, and regulate protein function[@b12][@b13][@b14][@b15]. Not until the last decade, however, has the discovery emerged that lncRNAs play an important role in diseases of the immune and nervous systems.

The first study implicating lncRNAs as regulators of the innate immune response showed that lincRNA-Cox2 is upregulated in mouse macrophages following exposure to lipopolysaccharide[@b16]. Subsequently, more lncRNAs were found to regulate the production of inflammatory mediators, such as LETHE, THRIL, NEAT1, PACER and IL-1β-RBT46[@b17][@b18]. A previous study focused on the involvement of lncRNA in modulating innate and adaptive immune responses, immune cell development, and differential expression of lncRNAs in autoimmune diseases[@b9]. In that context, although the pathogenesis of GBS has been extensively investigated, the exact molecular mechanism and epigenetic feature of this disease are still unclear. Therefore, establishing that lncRNA profiles are expressed differentially in GBS patients compared to their healthy counterparts is necessary and important.

In the present study, we investigated lncRNA and mRNA expression profiles in clinical samples from 15 GBS patients and 15 healthy controls using a microarray analysis. With mRMR software, we then ranked the mRNAs and lncRNAs according to their relevance to the class of GBS patients or healthy controls. The top 310 mRNAs and 114 lncRNAs were then identified according to their relevance to the class of GBS patients or healthy controls. These results indicated that these differentially expressed mRNAs and lncRNAs may be potential biomarkers for the diagnosis of GBS.

Based on the results of mRMR, GO and KEGG pathways, we proceeded to obtain detailed information on the biological functions and potential mechanisms of these mRNAs in GBS. GO analysis showed that these differentially expressed mRNAs based on mRMR results were enriched in top 29 GO (−lg^P^ \> 2.5), including the cytosol, cellular macromolecular complex assembly, cell cycle, ligase activity, and protein catabolic process, etc ([Fig. 3](#f3){ref-type="fig"} and [Table 3](#t3){ref-type="table"}). As shown in [Fig. 4](#f4){ref-type="fig"}, the top 310 mRNAs were associated with top seven major pathways, of which the "Proteasome" pathway was the most significant, as previously implicated in autoimmune diseases, especially GBS. The first report describing the role of proteasomes in autoimmune diseases noted that sera from patients with SLE contained specific autoantibodies against several polypeptide components of the proteasome[@b19]. Since then, patients with such autoimmune diseases as polymyositis-myositis and primary Sjogren's syndrome also had autoantibodies against proteasomes[@b20][@b21]. Mengual *et al.* had shown that patients with multiple sclerosis (MS) presented with B and T cell autoreactivity against the proteasome in glial and neuronal cells[@b22]. Mayo *et al.* later wrote that both serum and cerebrospinal fluid (CSF) of MS patients had antibodies to almost all the polypeptide components of the proteasome. Additionally, their titres of these antibodies were 5-10-fold higher in the sera than in the CSF. Moreover, the incidence of anti-proteasome seroreactivity samples from MS patients was significantly higher than that in those from individuals with other inflammatory diseases, such as SLE, Sjogren's syndrome, or sarcoidosis[@b23]. The previous study indicated that proteasome may be an antigenic target that evokes the cell-mediated immune response in MS patients and, possibly more generally, in several systemic inflammatory diseases.

GBS, as an acute inflammatory autoimmune disease affecting the peripheral nervous system, has attracted growing attention. Previous study showed that both the MB1 (X) and delta (Y) proteasome subunits were expressed in Schwann cells. Moreover, staining of the proteasome subunit delta (Y) was more abundant in peripheral nerves from GBS patients compared with those from inflammation-free controls[@b10]. Our present results from assessing the KEGG pathway in patients with GBS also indicated meaningful emphasis on the "Proteasome" pathway, an outcome that coincided with the previous studies[@b10] and reinforced the veracity of our results.

The co-expression network analysis cited here was constructed based on the 114 differentially expressed lncRNAs and the 310 differentially expressed mRNAs, *i.e.,* in comparisons between GBS patients and healthy controls. Results showed that a total of 113 lncRNAs and 303 mRNAs were included in the co-expression network. This co-expression network, which was composed of 5391 network nodes and 420 connections, indicated that one lncRNA could target at most 140 mRNAs and one mRNA could correlate with at most 53 lncRNAs (see File S3). We also found that 92 lncRNAs interacted with 6 mRNAs involved in the meaningful "Proteasome" pathway ([Fig. 5](#f5){ref-type="fig"}). This outcome suggests that the inter-regulation of lncRNAs and mRNAs is involved in the development of GBS and warrants further study.

In conclusion, the present study using microarray data provides newfound information regarding the potential role of mRNAs and lncRNAs in GBS patients. By using mRMR software, we also found top seven supposed KEGG pathways, especially a "Proteasome" pathway, and top 29 GO during GBS development. The co-expression network identified here also indicated the inter-regulation of lncRNAs and mRNAs in GBS patients. These findings may provide basic mechanistic information, possible biomarkers, and novel treatment strategies for patients afflicted with GBS.

Experimental Procedures
=======================

Patients and sample collection
------------------------------

For this study, we enrolled 15 GBS patients who fulfilled the standard diagnostic criteria for GBS in Tianjin Medical University General Hospital between 2014 and 2015[@b24]. When their blood was sampled, these patients were within the peak timing of manifesting GBS and before treatment with intravenous immune globulin (IVIG), plasma exchange or glucocorticoid. We also recruited 15 age- and gender-matched healthy controls for the comparative study. Informed consent was obtained at enrollment from all patients or legally acceptable surrogates. The study was carried out in accordance with the Declaration of Helsinki and with the Guide for Care and Use of Laboratory Animals as adopted and promulgated by the United National Institutes of Health. The present study was approved by the ethical review committees of Tianjin Medical University General Hospital. Peripheral blood anticoagulated by ethylene diamine tetraacetic acid (EDTA) was obtained from all GBS patients and healthy controls. Human PBMCs were isolated with Ficoll-Hypaque gradients.

RNA extraction
--------------

For RNA purification, we used Trizol reagent (Invitrogen) according to the manufacturer's instructions followed by application of PBMC to RNeasy spin columns (Qiagen, Venlo, Limburg, Netherlands). The RNA was quantified and the quality evaluated using a Nanodrop and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), respectively. The individual RNA samples were stored at −80 °C until further use.

Arraystar human lncRNA Microarray V3.0
--------------------------------------

The labeled cRNAs were hybridized onto the human LncRNA Expression Microarray V3.0 (Arraystar, Rockville, MD), which was designed for the global profiling of human lncRNAs and protein-coding transcripts. The third lncRNA microarray generated for each sample detected approximately 30586 lncRNAs and 26109 coding transcripts. Then, lncRNAs were carefully constructed using well-respected public transcriptome databases (Refseq, UCSC Known Genes, and Genecode), as well as landmark publications.

Quantitative Real-time PCR validation
-------------------------------------

Real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) is the gold standard for data verification. For the reverse transcriptase (RT) reaction, SYBR Green RT reagents (Bio-Rad, USA) were used. In brief, the RT reaction was performed for 60 min at 37 °C, followed by 60 min at 42 °C, using oligo (dT) and random hexamers. PCR amplifications were performed using SYBR Green Universal Master Mix. In brief, reactions were performed in duplicate containing 2× concentrated Universal Master Mix, 1 μL of template cDNA, and 100 nM of primers in a final volume of 12.5 μL, followed by analysis in a 96-well optical reaction plate (Bio-Rad). The lncRNA PCR results were quantified using the 2ΔΔct method against β-actin for normalization. The data represent the means of three experiments.

mRMR method
-----------

The mRMR method was used to rank the importance of all features[@b25][@b26][@b27]. The mRMR method ranks these features based on not only their relevance to the target, but also the redundancy between features. A smaller index of a feature indicates that the latter index provides a better trade-off between maximum relevance to the target and minimum redundancy. The mutual information (MI) function, which estimates the extent to which one vector is related to another, quantifies both relevance and redundancy. The MI is defined as:

In equation (1), x and y are vectors, p(x, y) is their joint probabilistic density, and p(x) and p(y) are the marginal probabilistic densities. V supposedly denotes the entire feature set. Vs denotes the already-selected feature set containing m features, and Vt is used to denote the to-be-selected feature set containing n features. The relevance D between the target c and the feature f in Vt can be calculated by:

The redundancy R between all the features in Vs and the feature f in Vt can be calculated by:

To determine the feature fj in Vt with maximum relevance and minimum redundancy, the mRMR function combines equation [(2)](#eq2){ref-type="disp-formula"} and equation [(3)](#eq3){ref-type="disp-formula"} and is defined as:

Then, the mRMR feature evaluation will continue N rounds when given a feature set with N (N = m+n) features. After evaluating the mRMR feature, a feature set S is obtained:

In this feature set S, the index h of each feature indicates at which round the feature is selected. The smaller the index h, the earlier the feature satisfies equation [(4)](#eq4){ref-type="disp-formula"} and the better the feature is.

GO and KEGG pathway analysis
----------------------------

GO was used to describe genes and gene product attributes, including cellular components, molecular functions, and biological processes. GO not only organizes genes into hierarchical categories but also uncovers the gene regulatory network on the basis of biologic processes and molecular functions[@b28]. KEGG mapping was used to predict the main pathways of the differentially expressed genes. DAVID method was used to select the main pathway with the significance threshold defined with *P* value and FDR[@b29].

Analysis of the lncRNA-mRNA co-expression network
-------------------------------------------------

Based on the correlation between the differentially expressed lncRNAs and mRNAs, the lncRNA-mRNA co-expression network was built. The network was constructed according to the normalized signal intensities of specific expression levels of mRNAs and lncRNAs. We used Pearson's correlation coefficients, equal to or greater than 0.8, to identify the lncRNAs and coding genes. Then, the lncRNA-mRNA co-expression network was constructed by Cytoscape software (The Cytoscape Consortium, San Diego, CA, USA).

Statistical analysis
--------------------

All statistical data were analyzed with SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Differences in lncRNA expression between the GBS patients and healthy controls were analyzed using mRMR software. Statistical differences were considered significant at *P* \< 0.05.
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![Hierarchical clustering of lncRNAs and mRNAs in GBS patients and healthy controls.\
G1-G4: GBS patients; H1-H4: healthy controls. The red and the green shades indicate the expression above and below the relative expression, respectively, across all samples. (**a**) lncRNA; (**b**) mRNA.](srep21819-f1){#f1}

![Validation of lncRNA microarray data by qRT-PCR. Three upregulated and three downregulated lncRNAs were validated by qRT-PCR of RNA extracted from PBMCs of 15 GBS patients and 15 healthy controls.\
The relative expression level of each lncRNA was normalized, and data displayed in histograms are expressed as means ± SD, \**P* \< 0.05 comparing GBS patients with healthy controls.](srep21819-f2){#f2}

![Top 29 gene ontology analysis.\
A total of 310 differentially expressed mRNAs were chosen based on the results of mRMR. The column graphs represent the enrichment of these mRNAs. The (−lg^P^) value was a positive correlation with GO. The (−lg^P^) values above 2.5 are presented. The top 29 GO are shown in detail in [Table 3.](#t3){ref-type="table"}](srep21819-f3){#f3}

![KEGG pathways.\
A total of 310 differentially expressed mRNAs were chosen based on the results of mRMR. The column graphs represent the enrichment of these mRNAs. The top seven significantly enriched KEGG pathways were calculated when plotted as the −lg^P^.](srep21819-f4){#f4}

![LncRNA-mRNA co-expression network in the "Proteasome" pathway.\
Here, 92 lncRNAs were interacting with 6 mRNAs in the meaningful "Proteasome" pathway.](srep21819-f5){#f5}

###### Significant mRNAs based on mRMR result.

  Order        mRNA       Order       mRNA       Order       mRNA
  ------- -------------- ------- -------------- ------- --------------
  1          SLC35C1       35        CYTH4        69       FAM190B
  2        LOC100507448    36        STK24        70        XRCC6
  3          SLC35D1       37        SPTAN1       71        SEPW1
  4          SLC35F2       38        STAT4        72       FAM160B1
  5          SLC31A1       39         DCXR        73       FAM115C
  6           ELFN1        40        DDOST        74        SEPHS1
  7            ELF2        41        SNURF        75       SH3KBP1
  8           ELMO1        42       B4GALT3       76         FER
  9            ELL         43        SNRPD2       77         RYK
  10          DTX3L        44        SNRPC        78        SACM1L
  11           AUP1        45        SPOCK2       79        FBXO7
  12          SLC9A6       46         DHX8        80        ZBTB2
  13          ELMO2        47       SPATA21       81        RUFY2
  14          ATP5O        48        SOX13        82        FGFRL1
  15          ESCO1        49         FRYL        83         ASL
  16          ESYT2        50       ZC3HAV1       84        SCNN1D
  17           SLA2        51        ARNTL        85        FAM40A
  18         EXOC3L1       52        ZBTB6        86         SDHD
  19          SHOC2        53        RPS14        87        FBXO31
  20          SHISA5       54         RRP1        88        GMEB1
  21          EWSR1        55         FMN1        89        CCDC12
  22           SKP1        56        RPL27        90        CCDC23
  23         SLC25A39      57         RPN1        91        TSEN54
  24         ATP6V1E1      58        ARPC4        92       TSPAN14
  25          ATP8A1       59        RPS11        93        TSHZ1
  26          EPB41        60        FNDC9        94        CASP5
  27          DTNBP1       61        ZDHHC4       95        TUBA1B
  28          SSBP4        62       ZDHHC20       96        CASP10
  29          SSNA1        63       RNF113B       97        CARD10
  30          DEFB1        64        RNASE3       98        CAPZA1
  31          DDX19B       65         RIN3        99       C12orf57
  32          DDX17        66        GDPD5        100        CD3E
  33          SREBF1       67       CYP11A1       101        CD48
  34          SRP14        68       FAM178B       102       CD244
  Order        mRNA       Order       mRNA       Order       mRNA
  103         TRIM56       139       CXCL5        175    LOC100130542
  104          CCNK        140       SUSD1        176       NR3C1
  105        CACNA2D4      141    XLOC_012444     177       ADAM12
  106        C22orf46      142      CTAGE15P      178        ADD1
  107         VCPIP1       143        TAP1        179       OBSCN
  108         VAMP5        144        BIN1        180        OGDH
  109        C21orf91      145       TACO1        181        LLPH
  110          VDR         146        BROX        182        ADAR
  111         VAMP2        147    XLOC_006443     183       PARP3
  112        C3orf36       148       CEP350       184        PHC3
  113          USP4        149      TOR1AIP1      185       PGRMC2
  114         USP47        150        TP73        186       PFDN5
  115         UTP18        151      CDK5RAP2      187       PI4K2B
  116          VWCE        152        TOE1        188       KANSL2
  117         VPRBP        153       CLASP1       189       KIF2A
  118       C20orf201      154       CLIC5        190       KIF22
  119        C19orf66      155       BRWD3        191      KIAA0947
  120         USP39        156      TMEM104       192      KIAA1715
  121         UBE2F        157       TM9SF2       193      KIAA1267
  122        C9orf173      158        TLE4        194       ABCD3
  123          UBP1        159       CHCHD3       195        MADD
  124        UBE2E4P       160       CHMP4A       196       MPZL2
  125        C5orf56       161      CIAPIN1       197       MAP2K7
  126        C17orf85      162       CHRM4        198        MR1
  127        C18orf25      163      ARHGAP30      199        LRP8
  128        C6orf136      164       L2HGDH       200       LPGAT1
  129         TCEB1        165       OR2A12       201       MAP3K4
  130         COX17        166       P4HA2        202       LSM14A
  131         TBC1D7       167       ZNF622       203       MIS12
  132          TBCA        168       KLRB1        204       9-Sep
  133         CNGB1        169     KRTAP10-3      205        MDH2
  134         THRAP3       170        P4HB        206        MDM1
  135         CORO7        171       PAPD7        207      METTL23
  136          CLPS        172       NSMCE1       208       MED15
  137        CWF19L1       173    LOC100127946    209       MESDC1
  138          CTU2        174    LOC100130342    210     LOC731932
  Order        mRNA       Order       mRNA       Order       mRNA
  211        MAPKAP1       247       PSMD11       283       ILDR1
  212         ABCA2        248        HCST        284        PPA1
  213         MAPRE2       249       PVRL1        285       POLR2L
  214         MAP3K7       250      HEATR7B1      286       PLXNA4
  215         AAGAB        251       AP2A1        287        IDS
  216      LOC100506191    252       Q9EPR2       288       ZNF350
  217      LOC100506047    253       PSMD4        289      PLEKHA2
  218      LOC100506906    254       PRKCB        290       IL10RA
  219          NEK9        255       HLA-F        291       IKBKG
  220          NGDN        256     HNRNPA1L2      292       AMPD2
  221         NIPA2        257       HNRNPD       293       AMOTL1
  222         ACTR3        258       APH1A        294      IL12RB1
  223        NEUROG1       259       PSMB1        295      ANAPC13
  224         ZNF728       260      HIST1H3C      296      ISG20L2
  225          NCK1        261        PRR5        297       PPP1R2
  226       LOC401480      262       PSMC3        298      PPP1R11
  227       LOC644285      263       PSMC5        299        ITCH
  228       LOC400128      264       PRPF6        300       ZNF24
  229        MYBBP1A       265        HK1         301      PPP2R1A
  230          MVP         266       ZNF207       302      HSP90AA2
  231          MSH6        267      ARFGAP2       303      HSD17B10
  232          MSRA        268       RB1CC1       304       ZNF26
  233       LOC648044      269       GPR108       305        AMH
  234         MYEOV2       270        GPN1        306        ISCU
  235          NBAS        271        RBL2        307        PPIB
  236         NAP1L4       272       GOLPH3       308        PMF1
  237         ACOX2        273        GMPS        309      PPP2R5D
  238       LOC200726      274       GNGT2        310       C1QL2
  239         N4BP2        275       RASA3                     
  240         HERC6        276       GSTP1                     
  241        HERPUD2       277       GSPT2                     
  242         HIPK2        278       RAB11B                    
  243          HEG1        279      ZMYND11                    
  244         HINT2        280       RANGRF                    
  245         PSME1        281       RAB8A                     
  246         HBS1L        282        RAC1                     

###### Significant lncRNAs based on mRMR result.

  Order         lncRNA         Order        lncRNA         Order    lncRNA
  ------- ------------------- ------- ------------------- ------- ----------
  1        ENSG00000262967.1    35        XLOC_004629       69     FAM190B
  2        ENSG00000263069.1    36     ENSG00000260194.1    70      XRCC6
  3            DL492557         37         AX748067         71      SEPW1
  4        ENSG00000234494.2    38         AX747809         72     FAM160B1
  5           XLOC_001920       39     ENSG00000260550.2    73     FAM115C
  6        ENSG00000234953.2    40         LOC644554        74      SEPHS1
  7           XLOC_003501       41        HIX0014588        75     SH3KBP1
  8           XLOC_003669       42         LOC729164        76       FER
  9           XLOC_003365       43        HIX0032156        77       RYK
  10       ENSG00000262721.1    44         LOC400027        78      SACM1L
  11           CR936829         45           nc082          79      FBXO7
  12          XLOC_001869       46     ENSG00000225407.3    80      ZBTB2
  13       ENSG00000233044.1    47          LIT3556         81      RUFY2
  14       ENSG00000232959.1    48     ENSG00000225886.1    82      FGFRL1
  15       ENSG00000267121.1    49          LIT3584         83       ASL
  16       ENSG00000266963.1    50     ENSG00000226266.2    84      SCNN1D
  17       ENSG00000266947.1    51          LIT3611         85      FAM40A
  18       ENSG00000266936.1    52       LOC100129203       86       SDHD
  19       ENSG00000233138.1    53     ENSG00000272700.1    87      FBXO31
  20       ENSG00000261609.1    54        HIX0213194        88      GMEB1
  21       ENSG00000266677.1    55     ENSG00000227258.1    89      CCDC12
  22          XLOC_000741       56         HOTAIRM1         90      CCDC23
  23       ENSG00000167117.4    57       LOC100653021       91      TSEN54
  24       ENSG00000150316.7    58     ENSG00000226849.1    92     TSPAN14
  25       ENSG00000237416.2    59       LOC100652739       93      TSHZ1
  26          XLOC_007231       60     ENSG00000269609.1    94      CASP5
  27       ENSG00000259260.1    61     ENSG00000203875.6    95      TUBA1B
  28       ENSG00000259115.1    62     ENSG00000203875.5    96      CASP10
  29            ASO3749         63     ENSG00000269371.1    97      CARD10
  30           AX747758         64          uc.263+         98      CAPZA1
  31       ENSG00000235609.3    65          uc.46-          99     C12orf57
  32           BC041623         66          uc.454-         100      CD3E
  33       ENSG00000235586.1    67     ENSG00000267827.1    101      CD48
  34          XLOC_005449       68     ENSG00000196364.7    102     CD244
  Order         lncRNA                                                 
  103      ENSG00000242973.2                                           
  104      ENSG00000244030.1                                           
  105          AK311257                                                
  106         XLOC_011769                                              
  107         XLOC_011339                                              
  108      ENSG00000249614.1                                           
  109      ENSG00000249478.1                                           
  110      ENSG00000243558.1                                           
  111          AL833150                                                
  112      ENSG00000255191.1                                           
  113          AK289390                                                
  114         XLOC_002473                                              

###### Top 29 GO analyses.

  Category                                                   Term                                                Count    \%     −lg^P^
  ------------ ------------------------------------------------------------------------------------------------ ------- ------- --------
  GO:0006511                            Ubiquitin-dependent protein catabolic process                             14     4.73    4.044
  GO:0005829                                               Cytosol                                                39     13.18   3.859
  GO:0000278                                          Mitotic cell cycle                                          17     5.74    3.737
  GO:0044093                              Positive regulation of molecular function                               22     7.43    3.589
  GO:0007049                                              Cell cycle                                              26     8.78    3.469
  GO:0034622                               Cellular macromolecular complex assembly                               15     5.07    3.409
  GO:0051437          Positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle           7     2.36    3.227
  GO:0051443                       Positive regulation of ubiquitin-protein ligase activity                        7     2.36    3.159
  GO:0051439              Regulation of ubiquitin-protein ligase activity during mitotic cell cycle                7     2.36    3.126
  GO:0051351                                Positive regulation of ligase activity                                 7     2.36    3.062
  GO:0051603                      Proteolysis involved in cellular protein catabolic process                      21     7.09    3.046
  GO:0044257                                  Cellular protein catabolic process                                  21     7.09    3.019
  GO:0034621                         Cellular macromolecular complex subunit organization                         15     5.07    2.918
  GO:0051438                           Regulation of ubiquitin-protein ligase activity                             7     2.36    2.911
  GO:0019941                           Modification-dependent protein catabolic process                           20     6.76    2.882
  GO:0043632                        Modification-dependent macromolecule catabolic process                        20     6.76    2.882
  GO:0030833                             Regulation of actin filament polymerization                               6     2.02    2.862
  GO:0030163                                      Protein catabolic process                                       21     7.09    2.857
  GO:0051340                                    Regulation of ligase activity                                      7     2.36    2.826
  GO:0044265                               Cellular macromolecule catabolic process                               23     7.77    2.772
  GO:0031398                            Positive regulation of protein ubiquitination                              7     2.36    2.744
  GO:0008064                        Regulation of actin polymerization or depolymerization                         6     2.03    2.625
  GO:0000502                                          Proteasome complex                                           6     2.03    2.602
  GO:0022402                                          Cell cycle process                                          19     6.42    2.576
  GO:0043085                              Positive regulation of catalytic activity                               18     6.08    2.574
  GO:0030832                                 Regulation of actin filament length                                   6     2.03    2.563
  GO:0065003                                   Macromolecular complex assembly                                    21     7.09    2.519
  GO:0031145    Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process     6     2.03    2.504
  GO:0051436          Negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle           6     2.03    2.504
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